Dr. Reddy’s AmVaz Approval Stayed; FDA Reconsiders Norvasc Competitor

FDA's stay of Dr. Reddy's AmVaz suggests the agency is taking another look at the amlodipine maleate NDA to bolster its response to Pfizer's scientific argument against use of the 505(b)(2) approval pathway